This series of bite-sized episodes will provide important information on MASLD and MASH in patients with type 2 diabetes. Drs. Naim Alkhouri and Robert Eckel and physician assistant Tessa Janovsky discuss best practices for screening, diagnosis, treatment, and management of MASH/MASLD.

Health Care Providers (HCPs) in the endocrinology specialty setting are challenged to be knowledgeable of the pathophysiology of MASLD (metabolic dysfunction-associated steatotic liver disease) and MASH (metabolic dysfunction-associated steatohepatitis) and its associated risk factors, as well as feel confident around how and when to order noninvasive diagnostic tests to prevent the emergence of more severe complications and stay on top of current guidelines and emerging treatment options.

Explore this interactive learning format, Build Your Own Case Study. By participating in this activity, you will gain valuable insights into effectively addressing MASLD/MASH for improved patient health.

GLI and the GLI NASH Council released the U.S. NASH Action Plan to comprehensively address NASH and its impact on patients and families, public health, and the economy.

To increase awareness of fatty liver disease, we all need to speak the same language. This framework for communication about NAFLD and NASH will help physicians, patients, caregivers, families, and advocates use the same wording to send a clear message: it’s time to increase awareness, diagnosis and treatment options for NASH.

A guide for those living with a NASH or NAFLD diagnosis.

Information about NASH and NAFLD, and tips for maintaining your liver health.